Akari Therapeutics PLC (ADR)  

(Public, NASDAQ:AKTX)   Watch this stock  
Find more results for AKTX
+0.01 (0.47%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.10 - 2.35
52 week 1.79 - 22.20
Open 2.12
Vol / Avg. 63,421.00/154,210.00
Mkt cap 32.50M
P/E     -
Div/yield     -
EPS -2.68
Shares 1.18B
Beta -7.82
Inst. own 0%
Mar 21, 2018
Q4 2017 Akari Therapeutics PLC Earnings Release - 9:30AM EDT - Add to calendar
Mar 21, 2018
Q4 2017 Akari Therapeutics PLC Earnings Call - 8:30AM EDT - Add to calendar
Feb 15, 2018
Akari Therapeutics PLC at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -152.79% -31.34%
Return on average equity -231.91% -43.81%
Employees 15 -
CDP Score - -


24 W 40th St Fl 8
NEW YORK, NY 10018-1028
United States - Map
+1-646-3500702 (Phone)
+1-646-8439352 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.

Officers and directors

Ray Prudo M.D. Chairman of the Board
Bio & Compensation  - Reuters
David Horn Solomon Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Dov Elefant Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Clive Richardson Chief Operating Officer, Director
Bio & Compensation  - Reuters
Nigel A.S. Hernandez Ph.D. Vice President - Worldwide Regulatory Affairs
Bio & Compensation  - Reuters
David Byrne Director
Bio & Compensation  - Reuters
Peter Feldschreiber Director
Bio & Compensation  - Reuters
Michael Grissinger Director
Bio & Compensation  - Reuters
Robert E. Ward Director
Age: 60
Bio & Compensation  - Reuters
Donald A. Williams Director
Age: 57
Bio & Compensation  - Reuters